Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (29725)	12/23/1999 9:16:00 AM
From: Torben Noerup Nielsen	Respond to of 32384

But it isn't exactly new news. Pfizer has been expected to do this. That said, I'm not unhappy with LGND's recent chart; it appears to be establishing a pattern of higher highs and higher lows. That's a trend... I still wonder where all the other compounds have gone. Ligand's pipeline is deep and there are quite a few other ones waiting in the wings. To their credit, Ligand's management does seem to have focused public attention on a few current ones and stopped confusing everyone by talking about too many at a time. The real booster would be human results for Targretin/Tamoxifen against ``mammary tumors" comparable to the pre-clinical ones. In that case, we might get a chance to feel what a Saturn 5 lift-off is like :-) Thanks, Torben